World supplier of antibodies, antigens and kits since 2007
Other Products
PROTAK™ dBET1
$160/ 2mg
Specification
QuantityTotal: $160
Ship worldwide. Contact order@enogene.com for ordering and bulk pricing or contact your local distributor.
Product Information
CAS No.1799711-21-9
Purity>98.00%
FormulaC38H37ClN8O7S
M.W.785.27
SolubilityDMSO : ≥ 50 mg/mL (63.67 mM);H2O : < 0.1 mg/mL (insoluble)
Storage/StabilityStore at -20°C
BackgrounddBET1 is a potent BRD4 protein degrader based on PROTAC technology with an EC50 of 430 nM.
Treatment with dBET1 down regulates MYC and PIM1 transcription. Degradation of BRD4 by dBET1 is associated with a more potent apoptotic consequence in MV4;11 cell line. Significantly increased apoptosis after only 4 h of dBET1 treatment is enhanced at 8 h. dBET1 also induces a potent and superior inhibitory effect on MV4;11 cell proliferation at 24 hours (measured by ATP content, IC50= 0.14 uM, compare to IC50= 1.1 uM with JQ1)[1].
Administration of dBET1 attenuates tumor progression as determined by serial volumetric measurement, and decreases tumor weight assessed post-mortem. Acute pharmacodynamic degradation of BRD4 is observed four hours after a first or second daily treatment with dBET1 (50 mg/kg IP). A statistically significant destabilization of BRD4, down regulation of MYC and inhibition of proliferation is observed with dBET1 compare to vehicle control in excised tumors. Two weeks of dBET1 is well tolerated by mice without a meaningful effect on weight, white blood count, hematocrit or platelet count[1].
Treatment with dBET1 down regulates MYC and PIM1 transcription. Degradation of BRD4 by dBET1 is associated with a more potent apoptotic consequence in MV4;11 cell line. Significantly increased apoptosis after only 4 h of dBET1 treatment is enhanced at 8 h. dBET1 also induces a potent and superior inhibitory effect on MV4;11 cell proliferation at 24 hours (measured by ATP content, IC50= 0.14 uM, compare to IC50= 1.1 uM with JQ1)[1].
Administration of dBET1 attenuates tumor progression as determined by serial volumetric measurement, and decreases tumor weight assessed post-mortem. Acute pharmacodynamic degradation of BRD4 is observed four hours after a first or second daily treatment with dBET1 (50 mg/kg IP). A statistically significant destabilization of BRD4, down regulation of MYC and inhibition of proliferation is observed with dBET1 compare to vehicle control in excised tumors. Two weeks of dBET1 is well tolerated by mice without a meaningful effect on weight, white blood count, hematocrit or platelet count[1].
Price160$
Categories by research area
Categories by product type
- Antibodies
- Primary Antibodies
- Tag antibodies
- Internal control antibodies
- Pathological (Immunohistochemistry, IHC) antibodies
- Cell Signal Transduction Research Antibodies
- Secondary Antibody
- Antibody Sampler Kits
- ELISA Kits
- Recombinant Proteins
- Fluorescence Reagents
- Signal Inhibitors and Activators
- Transfection Reagent
- Cell biology kits
- Overexpression Cell Lines
- Cell Lysates
- Purification Resins
- 2019-nCoV & Monkeypox